The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents

Haematologica. 2019 Jul;104(7):e307-e309. doi: 10.3324/haematol.2018.214759. Epub 2019 Jan 24.

Authors

Affiliations

¹ Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland.
² Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
³ Institute of Hematology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
⁴ Università della Svizzera Italiana, Institute of Oncology Research, Bellinzona, Switzerland frbertoni@mac.com.

No abstract available

Publication types

Letter

MeSH terms

Adenine / analogs & derivatives
Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors*
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
Cell Proliferation / drug effects*
Drug Synergism*
Humans
Hydrazines / administration & dosage
Lymphoma, B-Cell / drug therapy*
Lymphoma, B-Cell / pathology
Lymphoma, Mantle-Cell / drug therapy*
Lymphoma, Mantle-Cell / pathology
Niacinamide / administration & dosage
Niacinamide / analogs & derivatives
Piperidines / administration & dosage
Pyrazoles / administration & dosage
Pyrimidines / administration & dosage
Sulfonamides / administration & dosage
Triazoles / administration & dosage
Tumor Cells, Cultured

Substances

Bridged Bicyclo Compounds, Heterocyclic
Hydrazines
N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide
Piperidines
Pyrazoles
Pyrimidines
Sulfonamides
Triazoles
ibrutinib
Niacinamide
selinexor
zanubrutinib
Agammaglobulinaemia Tyrosine Kinase
BTK protein, human
Adenine
venetoclax